Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
Introduction We report the case of a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high who was treated with pembrolizumab after cabazitaxel administration. Case presentation A 58‐year‐old patient with heavily pretreated metastatic castration‐resistant...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-03-01
|
| Series: | IJU Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iju5.12144 |
| _version_ | 1818952595252707328 |
|---|---|
| author | Motohiro Fujiwara Yoshinobu Komai Takeshi Yuasa Noboru Numao Shinya Yamamoto Iwao Fukui Junji Yonese |
| author_facet | Motohiro Fujiwara Yoshinobu Komai Takeshi Yuasa Noboru Numao Shinya Yamamoto Iwao Fukui Junji Yonese |
| author_sort | Motohiro Fujiwara |
| collection | DOAJ |
| description | Introduction We report the case of a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high who was treated with pembrolizumab after cabazitaxel administration. Case presentation A 58‐year‐old patient with heavily pretreated metastatic castration‐resistant prostate cancer, whose prostate surgical specimen was disclosed as microsatellite instability‐high, underwent pembrolizumab therapy. After initiation of pembrolizumab, his prostate‐specific antigen level decreased, imaging findings showed good response with lymph node shrinkage, and his walking difficulty decreased dramatically. Conclusion The rarity of microsatellite instability‐high tumor in castration‐resistant prostate cancer may hamper pembrolizumab administration. This potentially active agent should be considered as part of a treatment regimen for patients with microsatellite instability‐high castration‐resistant prostate cancer. To the best of our knowledge, this is the first report of a Japanese castration‐resistant prostate cancer patient who demonstrated clinical benefit from pembrolizumab treatment. |
| first_indexed | 2024-12-20T09:52:52Z |
| format | Article |
| id | doaj.art-5ed1ab0ce6cc4f9e9843b676063c9b49 |
| institution | Directory Open Access Journal |
| issn | 2577-171X |
| language | English |
| last_indexed | 2024-12-20T09:52:52Z |
| publishDate | 2020-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | IJU Case Reports |
| spelling | doaj.art-5ed1ab0ce6cc4f9e9843b676063c9b492022-12-21T19:44:33ZengWileyIJU Case Reports2577-171X2020-03-0132626410.1002/iju5.12144Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐highMotohiro Fujiwara0Yoshinobu Komai1Takeshi Yuasa2Noboru Numao3Shinya Yamamoto4Iwao Fukui5Junji Yonese6Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo JapanDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo JapanDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo JapanDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo JapanDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo JapanDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo JapanDepartment of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo JapanIntroduction We report the case of a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high who was treated with pembrolizumab after cabazitaxel administration. Case presentation A 58‐year‐old patient with heavily pretreated metastatic castration‐resistant prostate cancer, whose prostate surgical specimen was disclosed as microsatellite instability‐high, underwent pembrolizumab therapy. After initiation of pembrolizumab, his prostate‐specific antigen level decreased, imaging findings showed good response with lymph node shrinkage, and his walking difficulty decreased dramatically. Conclusion The rarity of microsatellite instability‐high tumor in castration‐resistant prostate cancer may hamper pembrolizumab administration. This potentially active agent should be considered as part of a treatment regimen for patients with microsatellite instability‐high castration‐resistant prostate cancer. To the best of our knowledge, this is the first report of a Japanese castration‐resistant prostate cancer patient who demonstrated clinical benefit from pembrolizumab treatment.https://doi.org/10.1002/iju5.12144microsatellite instabilitypembrolizumabprostate cancer |
| spellingShingle | Motohiro Fujiwara Yoshinobu Komai Takeshi Yuasa Noboru Numao Shinya Yamamoto Iwao Fukui Junji Yonese Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high IJU Case Reports microsatellite instability pembrolizumab prostate cancer |
| title | Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high |
| title_full | Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high |
| title_fullStr | Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high |
| title_full_unstemmed | Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high |
| title_short | Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high |
| title_sort | pembrolizumab for a patient with metastatic castration resistant prostate cancer with microsatellite instability high |
| topic | microsatellite instability pembrolizumab prostate cancer |
| url | https://doi.org/10.1002/iju5.12144 |
| work_keys_str_mv | AT motohirofujiwara pembrolizumabforapatientwithmetastaticcastrationresistantprostatecancerwithmicrosatelliteinstabilityhigh AT yoshinobukomai pembrolizumabforapatientwithmetastaticcastrationresistantprostatecancerwithmicrosatelliteinstabilityhigh AT takeshiyuasa pembrolizumabforapatientwithmetastaticcastrationresistantprostatecancerwithmicrosatelliteinstabilityhigh AT noborunumao pembrolizumabforapatientwithmetastaticcastrationresistantprostatecancerwithmicrosatelliteinstabilityhigh AT shinyayamamoto pembrolizumabforapatientwithmetastaticcastrationresistantprostatecancerwithmicrosatelliteinstabilityhigh AT iwaofukui pembrolizumabforapatientwithmetastaticcastrationresistantprostatecancerwithmicrosatelliteinstabilityhigh AT junjiyonese pembrolizumabforapatientwithmetastaticcastrationresistantprostatecancerwithmicrosatelliteinstabilityhigh |